Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPremera Bluecross ADC Policy Update | OpenPayer
    Ask Trek AI about this page
    ModifiedPremera BluecrossPolicy 5.01.582

    Antibody-Drug Conjugate Coverage

    Customize your policy alerts

    Sign up for Premera Bluecross Policy 5.01.582 alerts

    Get alerted when Policy 5.01.582 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical-benefit coverage and prior authorization for specified antibody-drug conjugates used to treat cancer when labeled or policy-specific medical necessity criteria are met.

    Policy Summary
    PayerPremera Bluecross
    PolicyAntibody-Drug Conjugate Coverage
    Policy CodePolicy 5.01.582
    Change TypeModified
    Effective DateSeptember 1, 2026
    Last ReviewAug 11, 2026
    Next Review DateN/A
    Key ActionSubmit prior-authorization requests with drug-specific medical necessity documentation and supporting medical records.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Mylotarg coverage was expanded to include newly diagnosed CD33-positive acute myeloid leukemia.

    Zynlonta was added for relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

    Datroway coverage criteria were added.

    Adcetris and Polivy were moved into this antibody-drug conjugate policy from Policy 2.03.502.

    Padcev coverage was expanded to include combination treatment with pembrolizumab and berahyaluronidase alfa-pmph for locally advanced or metastatic urothelial cancer.

    The Padcev muscle-invasive bladder cancer criteria removed the requirement that the individual be ineligible for cisplatin-containing chemotherapy.

    The policy clarified that listed medications are subject to the product's FDA dosage and administration prescribing information.

    9Antibody-drug conjugates with listed coverage criteria
    3–12 monthsAuthorization duration
    InvestigationalUnlisted uses
    MedicalBenefit
    2026Most recent update

    Coverage Criteria

    Adcetris initial therapy

    Adcetris may be considered medically necessary when at least one of the following indications is met.

    Adcetris indications

    • Previously untreated stage III/IV cHL: Previously untreated stage III or IV classical Hodgkin lymphoma, in combination with chemotherapy.
    • Pediatric high-risk cHL: Age 2 years to less than 22 years with previously untreated high-risk classical Hodgkin lymphoma, defined as Ann Arbor stage IIB with bulk disease, IIIB, IVA, or IVB, in combination with AVE-PC.Age 2 to <22 years

      AVE-PC consists of doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.

    • Post-auto-HSCT consolidation: Classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation consolidation.
    • cHL after treatment failure: Classical Hodgkin lymphoma after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in an individual who is not an auto-HSCT candidate.At least 2 prior multi-agent regimens
    • Previously untreated sALCL/PTCL: Previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphoma, including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with chemotherapy.
    • sALCL after chemotherapy failure: Systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen.At least 1 prior multi-agent regimen
    • pcALCL/CD30-expressing MF: Primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides after prior systemic therapy.Prior systemic therapy
    • Relapsed/refractory LBCL: Relapsed or refractory large B-cell lymphoma, including DLBCL NOS, DLBCL arising from indolent lymphoma, or HGBL, after two or more lines of systemic therapy, when the individual is not eligible for auto-HSCT or CAR T-cell therapy, in combination with lenalidomide and a rituximab product.At least 2 systemic lines

    Besponsa initial therapy

    Besponsa may be considered medically necessary when all of the following are met.

    Besponsa criteria: The individual is aged 1 year or older and has relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.Age >=1 year

    Datroway initial therapy

    Datroway may be considered medically necessary when all criteria for one covered indication are met.

    Datroway indications

    • HR-positive/HER2-negative breast cancer: Age 18 years or older; unresectable or metastatic HR-positive, HER2-negative breast cancer; prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease; and prescribed by or in consultation with an oncologist.Age >=18 years

      HER2-negative is IHC 0, IHC 1+, or IHC 2+/ISH-.

    • Triple-negative breast cancer: Age 18 years or older; unresectable or metastatic triple-negative breast cancer; not a candidate for PD-1/PD-L1 inhibitor therapy; and prescribed by or in consultation with an oncologist.Age >=18 years
    • EGFR-mutated NSCLC:

    Elahere initial therapy

    Elahere may be considered medically necessary when all of the following are met.

    Elahere criteria: Age 18 years or older; folate receptor alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer; and one or more prior systemic treatment regimens.Age >=18 years; >=1 prior systemic regimen

    Emrelis initial therapy

    Emrelis may be considered medically necessary when all of the following are met.

    Emrelis criteria: Age 18 years or older; locally advanced or metastatic nonsquamous NSCLC; tumor with high c-Met protein overexpression; one or more prior lines of systemic therapy; and prescribed by or in consultation with an oncologist.Age >=18 years; c-Met >=50% of tumor cells with strong 3+ IHC staining; >=1 prior systemic line

    Mylotarg initial therapy

    Mylotarg may be considered medically necessary when at least one of the following indications is met.

    Mylotarg indications

    • Newly diagnosed AML: Newly diagnosed CD33-positive acute myeloid leukemia in an adult or pediatric individual aged 1 month or older.Age >=1 month for pediatric individuals
    • Relapsed/refractory AML: Relapsed or refractory CD33-positive acute myeloid leukemia in an adult or pediatric individual aged 2 years or older.Age >=2 years for pediatric individuals

    Padcev initial therapy

    Padcev may be considered medically necessary when at least one of the following indications is met.

    Padcev indications

    • Muscle-invasive bladder cancer: Age 18 years or older; Padcev is used with pembrolizumab or pembrolizumab plus berahyaluronidase alfa-pmph as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment.Age >=18 years
    • Locally advanced/metastatic urothelial cancer

      • Single-agent cisplatin-ineligible pathway: Ineligible for cisplatin-containing chemotherapy and previously received one or more prior lines of therapy.>=1 prior line
      • Prior PD-1/PD-L1 plus platinum pathway:

    Polivy initial therapy

    Polivy may be considered medically necessary when at least one of the following labeled indications is met.

    Polivy indications

    • Previously untreated DLBCL/HGBL: Adult with previously untreated DLBCL NOS or HGBL and IPI score of 2 or greater, in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP).IPI >=2

      See the First-Line Rituximab Agents related policy for the rituximab product.

    • Relapsed/refractory DLBCL: Adult with relapsed or refractory DLBCL NOS, in combination with bendamustine and a rituximab product or as bridging therapy prior to anti-CD19 CAR-T therapy.

      See related policies for rituximab products.

    Tivdak initial therapy

    Tivdak may be considered medically necessary when all of the following are met.

    Tivdak criteria: Age 18 years or older; recurrent or metastatic cervical cancer; and disease progression on or after chemotherapy.Age >=18 years

    Zynlonta initial therapy

    Zynlonta may be considered medically necessary when all of the following are met.

    Zynlonta criteria: Age 18 years or older; relapsed or refractory large B-cell lymphoma, including DLBCL NOS, DLBCL arising from low-grade lymphoma, or HGBL; and two or more lines of systemic therapy.Age >=18 years; >=2 systemic lines

    Reauthorization

    Continuation therapy requires that the applicable drug-specific criteria remain met and that clinical response is documented.

    Continuation criteria: The applicable drug-specific coverage criteria continue to be met and chart notes demonstrate that the individual continues to show a positive clinical response to therapy.

    Besponsa and Mylotarg may be authorized up to 6 months; Adcetris, Datroway, Elahere, Emrelis, Padcev, Polivy, Tivdak, and Zynlonta may be authorized up to 12 months.

    Padcev for muscle-invasive bladder cancer

    Padcev may be considered medically necessary for this muscle-invasive bladder cancer treatment setting when all of the following are met.

    Muscle-invasive bladder cancer: Adult patient with muscle-invasive bladder cancer receiving Padcev in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph as neoadjuvant treatment followed by continuation after cystectomy as adjuvant treatment.

    The September 2026 update removed the requirement that the individual be ineligible for cisplatin-containing chemotherapy.

    Datroway for unresectable or metastatic TNBC

    Datroway may be considered medically necessary when all of the following are met.

    Triple-negative breast cancer: Adult individual with unresectable or metastatic triple-negative breast cancer who is not a candidate for PD-1/PD-L1 inhibitor therapy.Age >=18 years

    Indication added in the 2026 interim review.

    Padcev for locally advanced or metastatic urothelial cancer

    Padcev may be considered medically necessary for this urothelial cancer combination indication when all of the following are met.

    Locally advanced or metastatic urothelial cancer: Adult individual with locally advanced or metastatic urothelial cancer treated with Padcev in combination with pembrolizumab; the policy later expanded the combination to include berahyaluronidase alfa-pmph.Age >=18 years

    The 2024 update removed the cisplatin-eligibility restriction for the pembrolizumab combination.

    All other uses of the medications listed in this policy are considered investigational. The medications are also subject to the product’s U.S. Food and Drug Administration (FDA) dosage and administration prescribing information.

    Coding and Clinical Thresholds

    HCPCS CodesHCPCSCovered
    C9174Injection, datopotamab deruxtecan-dlnk (Datroway), 1 mg (code termed 10/01/25)
    C9306Injection, telisotuzumab vedotin-tllv (Emrelis), 1 mg (code termed 01/01/26)
    J9011Injection, datopotamab deruxtecan-dlnk (Datroway), 1 mg (new code effective 10/01/25)
    HCPCS CodesHCPCSCovered
    J9042Injection, brentuximab vedotin (Adcetris), 1 mg
    J9063Injection, mirvetuximab soravtansine-gynx (Elahere), 1 mg
    J9177Injection, enfortumab vedotin-ejfv (Padcev), 0.25 mg
    J9203Injection, gemtuzumab ozogamicin (Mylotarg), 0.1 mg
    J9229Injection, inotuzumab ozogamicin (Besponsa), 0.1 mg
    J9273Injection, tisotumab vedotin-tftv (Tivdak), 1 mg
    J9309Injection, polatuzumab vedotin-piiq (Polivy), 1 mg
    J9326Injection, telisotuzumab vedotin-tllv, 1 mg (new code effective 01/01/26)
    J9359Injection, loncastuximab tesirine-lpyl (Zynlonta), 0.075 mg
    HCPCS coding updates and historical codesHCPCS
    J9229New HCPCS code effective 1/1/19
    J3490Removed HCPCS code
    J3590Added and later removed or re-added for listed drugs; added for Emrelis
    C9084Added HCPCS code; later termed and removed
    J9177Added for Tivdak
    J9273New HCPCS code
    J9359New HCPCS code
    C9146Added HCPCS code; later termed and removed
    J9063Added HCPCS code
    J9042Added for Adcetris
    1–10 of 15
    1/2
    High c-Met protein overexpression
    ThresholdAt least 50% of tumor cells with strong (3+) staining by immunohistochemistry (IHC).
    BiomarkerHigh c-Met protein overexpression.
    Coverage applicationRequired for Emrelis coverage in locally advanced or metastatic nonsquamous non-small cell lung cancer.
    Polivy initial-treatment IPI score
    Minimum scoreIPI score of 2 or greater.
    Treatment settingPreviously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified, or high-grade B-cell lymphoma (HGBL).

    Prior Authorization and Provider Requirements

    Prior Authorization

    Submit medical-benefit prior authorization

    Prior authorization applies to the listed antibody-drug conjugates, which are managed through the medical benefit. Document the drug-specific medical necessity criteria and submit supporting medical records.

    Prior Authorization

    Prior authorization is required

    The policy is administered under a prior-authorization utilization-management program. Submit requests for review under the applicable indication-specific criteria.

    Documentation Required

    Submit complete medical records

    Submit office visit notes documenting the diagnosis, relevant history, physical evaluation, and medication history, along with records supporting that the applicable medical necessity criteria are met.

    Antibody-Drug Conjugates

    Antibody-drug conjugates combine a monoclonal antibody with a cytotoxic chemotherapy payload. The antibody targets an antigen or cell-surface protein expressed by tumor cells, enabling internalization and intracellular release of the cytotoxic agent.

    Definitions and Abbreviations

    Antibody-drug conjugate
    TreatmentA treatment combining a monoclonal antibody with a chemotherapy drug.
    Targeting componentThe monoclonal antibody targets antigens on cancer cells.
    Drug releaseThe chemotherapy drug is released directly into the targeted cancer cells.
    HER2-negative
    IHC 0HER2-negative status includes IHC 0.
    IHC 1+HER2-negative status includes IHC 1+.
    IHC 2+/ISH-HER2-negative status includes IHC 2+ with a negative ISH result.

    Initial Therapy by Drug

    Adcetris — initial therapy coverage criteria

    Adcetris may be considered medically necessary when at least one of the following labeled indications is met.

    Adcetris indications

    • Previously untreated stage III or IV classical Hodgkin lymphoma, in combination with chemotherapy.
    • Age 2 years to less than 22 years with previously untreated high-risk classical Hodgkin lymphoma, defined as Ann Arbor stage IIB with bulk disease, IIIB, IVA, or IVB, in combination with AVE-PC.Age 2 to <22 years

      AVE-PC consists of doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.

    • Classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation consolidation.

    Continuation Therapy

    Continuation therapy — ongoing criteria and clinical response

    Continuation therapy requires ongoing satisfaction of drug-specific criteria and a documented positive clinical response.

    Drug-specific coverage criteria remain met and chart notes demonstrate that the individual continues to show a positive clinical response to therapy.

    Besponsa and Mylotarg may be authorized up to 6 months; Adcetris, Datroway, Elahere, Emrelis, Padcev, Polivy, Tivdak, and Zynlonta may be authorized up to 12 months.

    Policy Summary
    PayerPremera Bluecross
    PolicyAntibody-Drug Conjugate Coverage
    Policy CodePolicy 5.01.582
    Change TypeModified
    Effective DateSeptember 1, 2026
    Last ReviewAug 11, 2026
    Next Review DateN/A
    Key ActionSubmit prior-authorization requests with drug-specific medical necessity documentation and supporting medical records.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsPrior Authorization and Provider RequirementsAntibody-Drug ConjugatesDefinitions and AbbreviationsInitial Therapy by DrugContinuation Therapy
    Age 18 years or older; locally advanced or metastatic EGFR-mutated NSCLC; prior EGFR-directed therapy and platinum-based chemotherapy; and prescribed by or in consultation with an oncologist.
    Age >=18 years

    Examples of EGFR-directed therapy include afatinib, gefitinib, and osimertinib. Examples of platinum chemotherapy include cisplatin, carboplatin, and oxaliplatin.

    Previously received a PD-1 or PD-L1 inhibitor and platinum-containing chemotherapy.

    Examples include Keytruda, Imfinzi, Tecentriq, Bavencio, cisplatin, carboplatin, and oxaliplatin.

  1. Combination pathway: Used in combination with pembrolizumab or pembrolizumab plus berahyaluronidase alfa-pmph.
  2. Combination regimenPolivy in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
    Prior systemic therapy
    At least 1 line or regimenRequired for indications such as Elahere, Emrelis, or a Padcev single-agent pathway, as specified by the indication.
    At least 2 lines or regimensRequired for relapsed or refractory large B-cell lymphoma treated with Adcetris or Zynlonta, as applicable.
    Prior regimen examplesPrior endocrine-based therapy and chemotherapy for Datroway in HR-positive/HER2-negative breast cancer; prior EGFR-directed therapy and platinum-based chemotherapy for Datroway in EGFR-mutated NSCLC.
    Documentation Required

    Document continued clinical response

    For reauthorization, chart notes must demonstrate that the individual continues to show a positive clinical response to therapy.

    Denial Risk

    Unlisted uses may be denied

    Uses of the medications listed in this policy that are not specified as medically necessary are considered investigational and may be denied.

    Denial Risk

    Meet all drug-specific criteria

    Coverage may be denied when the drug-specific diagnosis, disease characteristics, age, prior-treatment history, combination regimen, biomarker, specialist-prescriber, or response requirements are not met.

    Denial Risk

    Insufficient response may prevent reauthorization

    Reauthorization may be denied when drug-specific criteria continue not to be met or chart notes do not demonstrate a positive clinical response to therapy.

    Denial Risk

    Follow the covered indication and FDA labeling

    Coverage may be denied when the requested antibody-drug conjugate does not meet the applicable indication-specific coverage criteria or is not administered according to the product's FDA dosage and administration prescribing information.

    High c-Met protein overexpression
    Tumor-cell thresholdAt least 50% of tumor cells.
    Staining intensityStrong (3+) staining.
    Testing methodImmunohistochemistry (IHC).
    Antibody-drug conjugate (ADC)
    ConstructA monoclonal antibody linked to a cytotoxic agent.
    Cellular processThe construct binds to a target antigen and is internalized.
    Therapeutic effectThe payload is released and causes tumor-cell death.
    CD19
    Protein typeA transmembrane protein.
    ExpressionExpressed on cells of B-lineage origin.
    Policy relevanceTargeted by loncastuximab tesirine-lpyl.
    CD30
    Protein familyA member of the tumor necrosis factor receptor family.
    sALCL expressionExpressed on systemic anaplastic large cell lymphoma cells.
    Classical Hodgkin lymphoma expressionExpressed on Hodgkin Reed-Sternberg cells in classical Hodgkin lymphoma.
    High c-Met protein overexpression in the LUMINOSITY study
    Tumor-cell thresholdAt least 50% of tumor cells.
    Staining intensityStrong 3+ staining.
    Staining locationMembrane and/or cytoplasmic staining.
    ADC
    AbbreviationADC.
    Expanded termAntibody-drug conjugate.
    Document usageUsed for antibody-drug conjugates such as polatuzumab and pinatuzumab.
    ALL
    AbbreviationALL.
    Expanded termAcute lymphoblastic leukemia.
    Policy contextUsed in the context of B-cell acute lymphoblastic leukemia treatment.
    AML
    AbbreviationAML.
    Expanded termAcute myeloid leukemia.
    Policy contextUsed in the context of CD33-positive acute myeloid leukemia treatment.
    DLBCL
    AbbreviationDLBCL.
    Expanded termDiffuse large B-cell lymphoma.
    Policy contextReferenced in relapsed or refractory lymphoma treatment criteria and evidence.
    VOD
    AbbreviationVOD.
    Expanded termHepatic veno-occlusive disease.
    Safety contextObserved with hepatotoxicity in the INO-VATE ALL trial of inotuzumab ozogamicin.
    Classical Hodgkin lymphoma after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in an individual who is not an auto-HSCT candidate.At least 2 prior multi-agent regimens
  3. Previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphoma, including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with chemotherapy.
  4. Systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen.At least 1 prior multi-agent regimen
  5. Primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides after prior systemic therapy.Prior systemic therapy
  6. Relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, when the individual is not eligible for auto-HSCT or CAR T-cell therapy, in combination with lenalidomide and a rituximab product.At least 2 systemic lines
  7. Besponsa — initial therapy coverage criteria

    Besponsa may be considered medically necessary when all of the following are met.

    The individual is aged 1 year or older and has relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.Age >=1 year

    Datroway — initial therapy coverage criteria

    Datroway may be considered medically necessary when all criteria for one covered indication are met.

    Datroway indications

    • Age 18 years or older; unresectable or metastatic HR-positive, HER2-negative breast cancer; prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease; and prescribed by or in consultation with an oncologist.Age >=18 years

      HER2-negative is IHC 0, IHC 1+, or IHC 2+/ISH-.

    • Age 18 years or older; unresectable or metastatic triple-negative breast cancer; not a candidate for PD-1/PD-L1 inhibitor therapy; and prescribed by or in consultation with an oncologist.Age >=18 years
    • Age 18 years or older; locally advanced or metastatic EGFR-mutated NSCLC; prior EGFR-directed therapy and platinum-based chemotherapy; and prescribed by or in consultation with an oncologist.Age >=18 years

    Elahere — initial therapy coverage criteria

    Elahere may be considered medically necessary when all of the following are met.

    Age 18 years or older; folate receptor alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer; and one or more prior systemic treatment regimens.Age >=18 years; >=1 prior systemic regimen

    Emrelis — initial therapy coverage criteria

    Emrelis may be considered medically necessary when all of the following are met.

    Age 18 years or older; locally advanced or metastatic nonsquamous NSCLC; tumor with high c-Met protein overexpression; one or more prior lines of systemic therapy; and prescribed by or in consultation with an oncologist.Age >=18 years; c-Met >=50% of tumor cells with strong 3+ IHC staining; >=1 prior systemic line

    Mylotarg — initial therapy coverage criteria

    Mylotarg may be considered medically necessary when at least one of the following indications is met.

    Mylotarg indications

    • Newly diagnosed CD33-positive acute myeloid leukemia in an adult or pediatric individual aged 1 month or older.Age >=1 month for pediatric individuals
    • Relapsed or refractory CD33-positive acute myeloid leukemia in an adult or pediatric individual aged 2 years or older.Age >=2 years for pediatric individuals

    Padcev — initial therapy coverage criteria

    Padcev may be considered medically necessary when at least one applicable indication is met.

    Padcev indications

    • Age 18 years or older; Padcev is used with pembrolizumab or pembrolizumab plus berahyaluronidase alfa-pmph as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment.Age >=18 years
    • ANY of the following

      • Ineligible for cisplatin-containing chemotherapy and previously received one or more prior lines of therapy.>=1 prior line
      • Previously received a PD-1 or PD-L1 inhibitor and platinum-containing chemotherapy.
      • Used in combination with pembrolizumab or pembrolizumab plus berahyaluronidase alfa-pmph.

    Polivy — initial therapy coverage criteria

    Polivy may be considered medically necessary when at least one labeled indication is met.

    Polivy indications

    • Adult with previously untreated DLBCL NOS or HGBL and IPI score of 2 or greater, in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP).IPI >=2
    • Adult with relapsed or refractory DLBCL NOS, in combination with bendamustine and a rituximab product or as bridging therapy prior to anti-CD19 CAR-T therapy.

    Tivdak — initial therapy coverage criteria

    Tivdak may be considered medically necessary when all of the following are met.

    Age 18 years or older; recurrent or metastatic cervical cancer; and disease progression on or after chemotherapy.Age >=18 years

    Zynlonta — initial therapy coverage criteria

    Zynlonta may be considered medically necessary when all of the following are met.

    Age 18 years or older; relapsed or refractory large B-cell lymphoma, including DLBCL NOS, DLBCL arising from low-grade lymphoma, or HGBL; and two or more lines of systemic therapy.Age >=18 years; >=2 systemic lines